Selected article for: "class ii and MHC class"

Author: Zhao, Jingxian; Zhao, Jincun; Fett, Craig; Trandem, Kathryn; Fleming, Erica; Perlman, Stanley
Title: IFN-?– and IL-10–expressing virus epitope-specific Foxp3(+) T reg cells in the central nervous system during encephalomyelitis
  • Document date: 2011_8_1
  • ID: k751ryv4_25
    Snippet: In summary, we demonstrate the presence of IFN--and IL-10-expressing virus-specific T reg cells in the CNS of infected mice and show that these T cells suppress proliferation of cognate epitope-specific CD4 T cells. Detection of epitopespecific T reg cells by cytokine expression may be especially useful because MHC class II/peptide tetramers are not widely available and may detect only high-affinity cells (Sabatino et al., 2011) . In addition,.....
    Document: In summary, we demonstrate the presence of IFN--and IL-10-expressing virus-specific T reg cells in the CNS of infected mice and show that these T cells suppress proliferation of cognate epitope-specific CD4 T cells. Detection of epitopespecific T reg cells by cytokine expression may be especially useful because MHC class II/peptide tetramers are not widely available and may detect only high-affinity cells (Sabatino et al., 2011) . In addition, previous efforts using T reg cells therapeutically to diminish excessive inflammatory responses have used adoptive transfer of in vitro propagated T reg cells (Tang et al., 2004; Tarbell et al., 2004) . Identification of virus-specific T reg cells raises the possibility that an alternative therapeutic approach will be to augment expansion of T reg cells specific for a virus or pathogenic self epitope at sites of inflammation.

    Search related documents:
    Co phrase search for related documents
    • infected mouse and inflammatory response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • infected mouse and reg cell: 1
    • infected mouse cns and inflammatory response: 1
    • inflammation site and reg cell: 1, 2
    • inflammatory response and reg cell: 1, 2
    • inflammatory response and therapeutic approach: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25